Literature DB >> 3700615

Response of dairy calves to vaccinia viruses that express foreign genes.

J H Gillespie, C Geissinger, F W Scott, W P Higgins, D F Holmes, M Perkus, S Mercer, E Paoletti.   

Abstract

Repeated intradermal inoculations of calves with wild-type vaccinia virus and recombinant vaccinia viruses expressing human hepatitis B virus surface antigen and herpes simplex virus, type 1, glycoprotein D produced characteristic pox lesions at each site of injection. In some instances, calves were inoculated as many as five times at intervals from 4 to 7 weeks. The lesions invariably were more severe after the second inoculation. Subsequent inoculations produced a less severe area of redness, swelling, necrosis, and scab formation. No other signs of illness, such as an elevation in temperature, were noted in the calves. Vaccinia virus was isolated in low titers from scabs taken at various times after inoculation. No lesions were formed at the sites injected with tissue culture fluid and cellular debris at the same time that virus inoculations were made. Calf contact controls remained normal through the 8-week exposure in isolation units with calves inoculated twice with vaccinia virus. No neutralizing antibody to vaccinia virus was detected in the contact controls. In contrast, the virus-inoculated calves developed neutralizing antibody to vaccinia virus and to herpes simplex virus glycoprotein D in serum. In all cattle, a second inoculation significantly enhanced the neutralizing antibody response within 1 week, suggesting that an anamnestic response had occurred. No antibody to hepatitis B virus surface antigen was elicited in calves after repeated inoculations with vaccinia recombinants that express hepatitis B virus surface antigen and are known to elicit in rabbits antibodies reactive with hepatitis B virus surface antigen.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3700615      PMCID: PMC268627          DOI: 10.1128/jcm.23.2.283-288.1986

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  17 in total

1.  Two major DNA variants present in serially propagated stocks of the WR strain of vaccinia virus.

Authors:  D Panicali; S W Davis; S R Mercer; E Paoletti
Journal:  J Virol       Date:  1981-03       Impact factor: 5.103

2.  Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen.

Authors:  G L Smith; M Mackett; B Moss
Journal:  Nature       Date:  1983-04-07       Impact factor: 49.962

3.  Vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D prevents latent herpes in mice.

Authors:  K J Cremer; M Mackett; C Wohlenberg; A L Notkins; B Moss
Journal:  Science       Date:  1985-05-10       Impact factor: 47.728

4.  Molecular genetics of vaccinia virus: demonstration of marker rescue.

Authors:  E Nakano; D Panicali; E Paoletti
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

5.  Vaccinia virus: a selectable eukaryotic cloning and expression vector.

Authors:  M Mackett; G L Smith; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

6.  Herpes simplex virus type-1 glycoprotein D gene: nucleotide sequence and expression in Escherichia coli.

Authors:  R J Watson; J H Weis; J S Salstrom; L W Enquist
Journal:  Science       Date:  1982-10-22       Impact factor: 47.728

7.  Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus.

Authors:  D Panicali; E Paoletti
Journal:  Proc Natl Acad Sci U S A       Date:  1982-08       Impact factor: 11.205

8.  Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene.

Authors:  T J Wiktor; R I Macfarlan; K J Reagan; B Dietzschold; P J Curtis; W H Wunner; M P Kieny; R Lathe; J P Lecocq; M Mackett
Journal:  Proc Natl Acad Sci U S A       Date:  1984-11       Impact factor: 11.205

9.  Expression of rabies virus glycoprotein from a recombinant vaccinia virus.

Authors:  M P Kieny; R Lathe; R Drillien; D Spehner; S Skory; D Schmitt; T Wiktor; H Koprowski; J P Lecocq
Journal:  Nature       Date:  1984 Nov 8-14       Impact factor: 49.962

10.  Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes.

Authors:  J W Yewdell; J R Bennink; G L Smith; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

View more
  3 in total

Review 1.  Vaccinia virus vectors: new strategies for producing recombinant vaccines.

Authors:  D E Hruby
Journal:  Clin Microbiol Rev       Date:  1990-04       Impact factor: 26.132

2.  Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination.

Authors:  J F Rooney; C Wohlenberg; K J Cremer; B Moss; A L Notkins
Journal:  J Virol       Date:  1988-05       Impact factor: 5.103

3.  Raccoon poxvirus rabies virus glycoprotein recombinant vaccine in sheep.

Authors:  J C DeMartini; H M Bickle; S J Brodie; B X He; J J Esposito
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.